When did Pacific Biosciences of California report Q4 2024 earnings?

Pacific Biosciences of California (PACB) reported Q4 2024 earnings on February 13, 2025 after market close.

What were Pacific Biosciences of California's Q4 2024 revenue and EPS?

Pacific Biosciences of California reported revenue of $39.2M and eps of $-0.20 for Q4 2024.

Did Pacific Biosciences of California beat estimates in Q4 2024?

Revenue missed the consensus estimate of $40.7M by $1.5M. EPS beat the consensus estimate of $-0.20 by $0.00.

Where can I find Pacific Biosciences of California's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001299130-25-000061) directly on SEC EDGAR. The filing index links above go to sec.gov.

Pacific Biosciences of California PACB Q4 2024 Annual earnings

Reported February 13, 2025 · After market close

Revenue$39.2MMiss by $1.5M

EPS-$0.20In line

Revenue estimate$40.7M

EPS estimate-$0.20

Next report

Aug 3, 2026 (In 5 days)

Revenue estimate$42.9M

EPS estimate-$0.13

Financials

Q4 2024

Income statement

See full

Revenue$39.2M-32.8%

Gross profit$10.1M+5.1%

Operating income-$153.0M-74.8%

Net income-+100%

EPS (diluted)-$0.44-41.9%

Balance sheet

See full

Cash & equivalents$57.6M-68.5%

Total debt$24.9M-40.2%

Total equity$506.6M-27.8%

Total assets$1.3B-27.8%

Cash flow

See full

Operating cash flow-$30.7M+46.8%

CapEx$1.6M-20.1%

Free cash flow-$32.3M+45.8%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$538.6M-79.4%

Enterprise value$505.94M-79.6%

P/S3.5×-9.6×

Profitability

See full

Gross margin24.2%-2.1pp

Operating margin-308%+1,696pp

Net margin-202.7%+97.7pp

FCF margin-137.8%+4.4pp

Returns & leverage

See full

Return on equity-51.7%+3.6pp

Debt / equity0×0.0×

Current ratio7.5×-0.3×

Segments

By geography

See full

Americas$20.2M—

Europe, Middle East and Africa$10.1M—

Asia-Pacific$9.0M-34.2%

By product

See full

Consumable revenue$18.8M+18.7%

Instrument revenue$15.3M-49.2%

Service And Other$5.1M+23.2%

By segment

See full

Reportable Segment$39.2M-21.8%

Versus estimates

Revenue

Q1 2026$37.2MMiss by $2.8M Q4 2025$44.6MBeat by $1.6M Q3 2025$38.4MMiss by $6.2M Q2 2025$39.8MMiss by $181.9K Q1 2025$37.2MBeat by $253.0K

Q4 2024$39.2MMiss by $1.5M

Diluted EPS

Q1 2026-$0.12Beat by $0.05 Q4 2025-$0.12Beat by $0.07 Q3 2025-$0.12Beat by $0.04 Q2 2025-$0.13Beat by $0.05 Q1 2025-$0.15Beat by $0.04

Q4 2024-$0.20In line

Ask the moment Pacific Biosciences of California reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Pacific Biosciences of California report Q4 2024 earnings?: Pacific Biosciences of California (PACB) reported Q4 2024 earnings on February 13, 2025 after market close.
What were Pacific Biosciences of California's Q4 2024 revenue and EPS?: Pacific Biosciences of California reported revenue of $39.2M and eps of $-0.20 for Q4 2024.
Did Pacific Biosciences of California beat estimates in Q4 2024?: Revenue missed the consensus estimate of $40.7M by $1.5M. EPS beat the consensus estimate of $-0.20 by $0.00.
Where can I find Pacific Biosciences of California's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001299130-25-000061) directly on SEC EDGAR. The filing index links above go to sec.gov.